BTK
30 programs · 28 companies
Programs
30
Companies
28
Active Trials
11
Targeting BTK
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | Alzheimer'sRCC | |
| RHH-8482 | Roche | Phase 1 | Alzheimer'sLN | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | Pompe | |
| 369-8021 | Hansoh Pharma | Approved | DMD | |
| Pemitinib | Xenon Pharma | Preclinical | Endometrial CaProstate Ca | |
| Terazumab | Rapport Ther | Phase 2 | FSGSPV | |
| CSL-7919 | CSL Limited | Preclinical | Endometrial CaHemophilia A | |
| PHA-4842 | Pharming | Approved | MelanomaHNSCC | |
| Pexazanubrutinib | Pharming | Phase 1/2 | PNHPancreatic Ca | |
| Sotobrutinib | Sihuan Pharma | NDA/BLA | CFFTD | |
| Ribomavacamten | Nuvation Bio | Phase 3 | MDDHuntington's | |
| SAV-5205 | Cassava Sci | NDA/BLA | Parkinson'sPsoriasis | |
| Datocapivasertib | Deerfield Mgmt | Phase 2/3 | HNSCC | |
| THI-2182 | Third Rock | Phase 1/2 | ACC | |
| AAD-5814 | Aadi Biosciences | Phase 2 | T2DLN | |
| Niratuximab | Pharmacyclics (AbbVie) | Phase 1 | NMOSDPAH | |
| Gelilemzoparlimab | Betta Pharma | Preclinical | DMD | |
| MAS-IIT-445 | Mass General | NDA/BLA | Psoriasis | |
| Datomavacamten | Entrada Ther | Approved | Wilms | |
| 459-1094 | Healios | Phase 3 | SCDHS | |
| Cevinaritide | Laurus Labs | Preclinical | MDS | |
| Olpaderotide | Abcam (Danaher) | Phase 2 | Thymoma | |
| AUT-9774 | Autolus Ther | Phase 2/3 | HSMCC | |
| Ivotinib | Chiesi | Phase 3 | CTCL | |
| Gelitenlimab | Chiesi | Phase 1/2 | ACCPsA | |
| Motamavacamten | JHL Biotech | Phase 3 | HSRSV | |
| Tiraderotide | Richmond Lab | Phase 2 | OCDEwing Sarcoma | |
| VIN-3660 | Vingroup Biotech | Phase 2 | Celiac | |
| NAT-IIT-338 | Natl Taiwan Univ Hosp | Approved | CRC | |
| Lisosertib | Helsinn | Phase 1 | NSCLC |